Remove tag aim
article thumbnail

STAT+: Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices

STAT

Two recent studies aimed to quantify how much R&D costs impact a drug’s price, and how much a drug’s effectiveness correlates with its price — factors that might, in theory, help justify a sizable price tag. But neither factor has much effect, the studies concluded.

97
article thumbnail

Jolly Good/Teijin Pharma develop VR digital therapeutics for depression

pharmaphorum

Using technologies such as VR and AI, the company aims to accelerate human growth and social rehabilitation in medical education and provide support for people with disabilities, as well as provide treatments for mental illness. The post Jolly Good/Teijin Pharma develop VR digital therapeutics for depression appeared first on.

Hospitals 122
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Pharmalittle: New York officials press pharmacy chains over abortion pill; Sanders pushes bill for $20 insulin cap

STAT

 Two recent studies aimed to quantify how much R&D costs impact a drug’s price, and how much effectiveness correlates with its price — factors that might, in theory, help justify a sizable price tag. But neither factor has much effect, the studies concluded.

75
article thumbnail

J&J gets first approval for multiple myeloma bispecific Tecvayli

pharmaphorum

The double-headed antibody binds to CD3 on T cells and redirects them to BCMA-expressing myeloma cells, with the aim of stimulating an immune attack on the tumour, which remains incurable despite a slew of new therapies reaching the market in recent years.

FDA 97
article thumbnail

Blue Note leukaemia DTx gets FDA breakthrough tag

pharmaphorum

Other DTxs are aimed at people being treated for breast and lung cancers. The post Blue Note leukaemia DTx gets FDA breakthrough tag appeared first on. In 2020, it formed an alliance with Memorial Sloan Kettering Cancer Centre in the US to develop an app that can be used by patients who are living in fear of their cancer, for example.

FDA 64
article thumbnail

Versanis’ bimagrumab, first-in-class obesity therapy, enters Phase IIb of development

Pharmaceutical Technology

On January 12, Versanis Bio announced that enrollment had begun for its Phase IIb trial, BELIEVE (NCT05616013), which aims to study bimagrumab’s (BYM-338) efficacy and safety in the US, among other locations. Despite its high price tag, bimagrumab’s unique features set it apart from currently marketed therapies.

article thumbnail

Can gene therapies for haemophilia defend their high price tags?

Pharmaceutical Technology

On November 2, the Institute for Clinical and Economic Review (ICER) released its updated evidence aimed at measuring the clinical effectiveness and cost of the two haemophilia gene therapies. million price tag. The post Can gene therapies for haemophilia defend their high price tags? million ($1.8 million at the time).

FDA 111